相关实验视频
Updated: Jun 15, 2025

08:35
Inducible and Reversible Dominant-negative DN Protein Inhibition
Published on: January 7, 2019
8.4K
经典和诱导近距离抑制剂的正交电阻机制
Manuel L Merz1,2, Karishma Kailass1,3,2, Rajaiah Pergu1,2
1Chemical Biology and Therapeutics Science, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
bioRxiv : the preprint server for biology
|June 4, 2025
概括
药物耐药性是一个重大挑战. 诱导接近性抑制剂提供了一种新的策略,通过采用不同的抵抗机制来克服对传统药物的耐药性.
科学领域:
- 在瘤学瘤学.
- 药物发现 药物发现 药物发现
- 分子生物学分子生物学
背景情况:
- 耐药性是癌症治疗的一个重要障碍,需要新的治疗策略.
- 经典抑制剂通常由于特定的抵抗机制而面临阻力.
- 诱导接近模式代表了一种新型的治疗方法,具有独特的作用机制.
研究的目的:
- 与经典抑制剂相比,研究诱导近距离抑制剂的耐药性机制.
- 探索诱导近距离抑制剂在克服耐药性的潜力.
- 为了利用基准编辑器造突变发生查来优先考虑新药候选药物.
主要方法:
- 雇佣了基准编辑器,使用KRAS作为模型系统进行基因突变查.
- 分析了诱导近距离抑制剂与经典抑制剂的耐药性概况.
- 通过诱导近距离模式对三元复合物的形成进行了表征,而不是通过经典抑制剂对二元复合物的形成.
主要成果:
- 与古典抑制剂相比,诱导接近性抑制剂表现出直角抗性机制,即使具有重叠的结合位点.
- 基编辑器突变发生屏幕有效识别了具有明显耐药性概况的抑制剂.
- 为了验证这些发现,KRAS被用作模型系统.
结论:
- 诱导接近抑制剂可以绕过与经典抑制剂相关的抵抗机制.
- 基编辑器突变发生屏幕是发现和优先考虑具有正交抗性机制的药物的宝贵工具.
- 诱导接近模式在癌症治疗中克服获得的耐药性方面具有显著的前景.
相关概念视频
Induced-fit Model
80.6K
Most chemical reactions in cells require enzymes—biological catalysts that speed up the reaction without being consumed or permanently changed. They reduce the activation energy needed to convert the reactants into products. Enzymes are proteins, that usually work by binding to a substrate—a reactant molecule that they act upon.
Enzymes exhibit substrate specificity, meaning that they can only bind to certain substrates. This is mainly determined by the shape and chemical...
Enzymes exhibit substrate specificity, meaning that they can only bind to certain substrates. This is mainly determined by the shape and chemical...
80.6K
Indirect-Acting Cholinergic Agonists: Mechanism of Action
1.8K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.8K
Protein-protein Interfaces
12.5K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
12.5K
Enzyme Inhibition
78.1K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
78.1K
Enzymes
81.2K
Inside living organisms, enzymes act as catalysts for many biochemical reactions involved in cellular metabolism. The role of enzymes is to reduce the activation energies of biochemical reactions by forming complexes with its substrates. The lowering of activation energies favor an increase in the rates of biochemical reactions.
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
81.2K
Drug-Receptor Interaction: Antagonist
2.8K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Antagonists can be classified as competitive or noncompetitive based on their...
2.8K

